Eagle Pharmaceuticals Inc Asset Resilience Ratio
Eagle Pharmaceuticals Inc asset resilience ratio. Eagle Pharmaceuticals Inc (EGRX) has an Asset Resilience Ratio of 1.49% as of June 2022. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See EGRX cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Eagle Pharmaceuticals Inc (2012–2021)
Asset resilience ratio of Eagle Pharmaceuticals Inc from 2012 to 2021. This chart shows how Eagle Pharmaceuticals Inc's Asset Resilience Ratio has changed over time. Read Eagle Pharmaceuticals Inc balance sheet liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Eagle Pharmaceuticals Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see balance sheet size of Eagle Pharmaceuticals Inc.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $5.68 Million | 1.49% |
| Total Liquid Assets | $5.68 Million | 1.49% |
Asset Resilience Insights
- Limited Liquidity: Eagle Pharmaceuticals Inc maintains only 1.49% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Eagle Pharmaceuticals Inc Industry Peers by Asset Resilience Ratio
Compare Eagle Pharmaceuticals Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Takeda Pharmaceutical Company Limited
F:TKDA |
Drug Manufacturers - Specialty & Generic | 0.69% |
|
Galderma Group N
SW:GALD |
Drug Manufacturers - Specialty & Generic | 3.56% |
|
Enzymatica publ AB
ST:ENZY |
Drug Manufacturers - Specialty & Generic | 22.17% |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603 |
Drug Manufacturers - Specialty & Generic | 9.04% |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566 |
Drug Manufacturers - Specialty & Generic | 47.16% |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518 |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Walvax BioTech
SHE:300142 |
Drug Manufacturers - Specialty & Generic | 2.20% |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858 |
Drug Manufacturers - Specialty & Generic | 3.47% |
Eagle Pharmaceuticals Inc Asset Resilience Ratio by Year (2012–2021)
Eagle Pharmaceuticals Inc asset resilience ratio by year from 2012 to 2021. The table below shows the annual Asset Resilience Ratio data for Eagle Pharmaceuticals Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2021-12-31 | 1.96% | $4.98 Million | $253.73 Million | -- |
| 2017-12-31 | 0.00% | $0.00 | $270.06 Million | -- |
| 2016-12-31 | 0.00% | $0.00 | $213.57 Million | -- |
| 2015-12-31 | 0.00% | $0.00 | $124.61 Million | -- |
| 2014-12-31 | 37.44% | $20.00 Million | $53.41 Million | +21.55pp |
| 2012-12-31 | 15.89% | $1.50 Million | $9.44 Million | -- |
About Eagle Pharmaceuticals Inc
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on manufacturing, developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company's product portfolio offers RYANODEX for malignant hyperthermia; and BELRAPZO and BENDEKA for chronic lymphocytic leukemia and indolent B-cell non… Read more